drugset / Trial / NCT01794299

Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

NCT01794299 ↗

Phase 2 Completed 31 enrolled Kiadis Pharma
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related haploidentical donor.

Timeline

Start
2013-03
Primary completion
2016-06
Completion
2017-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ATIR Cell therapy 2e+06 cells/kg Intravenous